𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy

✍ Scribed by Ayalew Tefferi

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
117 KB
Volume
83
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Leukemogenic risk of hydroxyurea therapy
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
✍ Nand, Sucha; Stock, Wendy; Godwin, John; Fisher, Susan Gross πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 417 KB πŸ‘ 2 views

In polycythemia Vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%. This risk has been estimated to be 1-5.9% with hydroxyurea (HU) therapy. When compared with historical controls, the risk with use of HU does not a

Leukocytosis at diagnosis and the risk o
Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera
✍ Naseema Gangat; Alexandra P. Wolanskyj; Susan M. Schwager; Curtis A. Hanson; Aya πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 144 KB

## Abstract ## BACKGROUND: Advanced age and a history of thrombosis were well‐established risk factors for thrombosis in essential thrombocythemia (ET) and polycythemia vera (PV); cytoreductive therapy was indicated in their presence. Recent studies have suggested leukocytosis as an additional ris